TG Therapeutics Inc.（TGTX）周一盘中股价大跌13.45%，引发市场关注。这家生物制药公司今日公布的第二季度财报显示业绩未能达到分析师预期，导致投资者信心受挫。
根据公司发布的财报，截至6月30日的季度调整后每股收益为0.17美元，低于分析师平均预期的0.22美元。虽然较去年同期的0.04美元有所增长，但未能满足市场预期。公司季度营收同比增长92.1%，达到1.4115亿美元，但仍低于分析师预期的1.4738亿美元。
尽管本季度业绩不及预期，但分析师对TG Therapeutics的长期前景仍保持乐观态度。目前，分析师对该公司股票的平均评级为"买入"，12个月目标价中位数为46.00美元，较上一交易日收盘价35.02美元高出约23.9%。然而，投资者似乎更关注短期业绩，导致股价出现大幅下跌。值得注意的是，TG Therapeutics今年迄今为止的股价仍上涨了16.3%，显示出公司在生物制药领域的潜力。未来公司能否改善业绩表现，将继续受到市场密切关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.